Literature DB >> 24804827

Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.

Laura C O'Brien1, Eleonora Mezzaroma2, Benjamin W Van Tassell2, Carlo Marchetti3, Salvatore Carbone3, Antonio Abbate4, Stefano Toldo3.   

Abstract

Interleukin 18 (IL-18) is a proinflammatory cytokine in the IL-1 family that has been implicated in a number of disease states. In animal models of acute myocardial infarction (AMI), pressure overload, and LPS-induced dysfunction, IL-18 regulates cardiomyocyte hypertrophy and induces cardiac contractile dysfunction and extracellular matrix remodeling. In patients, high IL-18 levels correlate with increased risk of developing cardiovascular disease (CVD) and with a worse prognosis in patients with established CVD. Two strategies have been used to counter the effects of IL-18:IL-18 binding protein (IL-18BP), a naturally occurring protein, and a neutralizing IL-18 antibody. Recombinant human IL-18BP (r-hIL-18BP) has been investigated in animal studies and in phase I/II clinical trials for psoriasis and rheumatoid arthritis. A phase II clinical trial using a humanized monoclonal IL-18 antibody for type 2 diabetes is ongoing. Here we review the literature regarding the role of IL-18 in AMI and heart failure and the evidence and challenges of using IL-18BP and blocking IL-18 antibodies as a therapeutic strategy in patients with heart disease.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24804827      PMCID： PMC4069269          DOI： 10.2119/molmed.2014.00034

Source DB:  PubMed          Journal:  Mol Med        ISSN： 1076-1551            Impact factor:   6.354


  99 in total

Review 1.  Catecholamines, cardiac beta-adrenergic receptors, and heart failure.

Authors:  R J Lefkowitz; H A Rockman; W J Koch
Journal:  Circulation       Date:  2000-04-11       Impact factor: 29.690

2.  Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18.

Authors:  S H Kim; M Eisenstein; L Reznikov; G Fantuzzi; D Novick; M Rubinstein; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

3.  Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury.

Authors:  Masanori Kawaguchi; Masafumi Takahashi; Takeki Hata; Yuichiro Kashima; Fumitake Usui; Hajime Morimoto; Atsushi Izawa; Yasuko Takahashi; Junya Masumoto; Jun Koyama; Minoru Hongo; Tetsuo Noda; Jun Nakayama; Junji Sagara; Shun'ichiro Taniguchi; Uichi Ikeda
Journal:  Circulation       Date:  2011-01-31       Impact factor: 29.690

Review 4.  NLRP3 inflammasome as a novel player in myocardial infarction.

Authors:  Masafumi Takahashi
Journal:  Int Heart J       Date:  2014-03-14       Impact factor: 1.862

5.  Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells.

Authors:  A J Puren; G Fantuzzi; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

6.  Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta.

Authors:  B J Pomerantz; L L Reznikov; A H Harken; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

7.  Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1beta.

Authors:  M G Netea; B J Kullberg; I Verschueren; J W Van Der Meer
Journal:  Eur J Immunol       Date:  2000-10       Impact factor: 5.532

8.  Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme.

Authors:  Y Gu; K Kuida; H Tsutsui; G Ku; K Hsiao; M A Fleming; N Hayashi; K Higashino; H Okamura; K Nakanishi; M Kurimoto; T Tanimoto; R A Flavell; V Sato; M W Harding; D J Livingston; M S Su
Journal:  Science       Date:  1997-01-10       Impact factor: 47.728

9.  IL-18 contributes to host resistance against infection with Pseudomonas aeruginosa through induction of IFN-gamma production.

Authors:  Xi Huang; Sharon A McClellan; Ronald P Barrett; Linda D Hazlett
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

Review 10.  Targeting interleukin-1 in heart disease.

Authors:  Benjamin W Van Tassell; Stefano Toldo; Eleonora Mezzaroma; Antonio Abbate
Journal:  Circulation       Date:  2013-10-22       Impact factor: 29.690
View more
  38 in total

Review 1.  Inflammation in nonischemic heart disease: initiation by cardiomyocyte CaMKII and NLRP3 inflammasome signaling.

Authors:  Takeshi Suetomi; Shigeki Miyamoto; Joan Heller Brown
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-23       Impact factor: 4.733

Review 2.  The NLRP3 inflammasome in acute myocardial infarction.

Authors:  Stefano Toldo; Antonio Abbate
Journal:  Nat Rev Cardiol       Date:  2017-11-16       Impact factor: 32.419

3.  Increased IL18 mRNA levels in peripheral artery disease and its association with triglyceride and LDL cholesterol levels: a pilot study.

Authors:  Serkan Burc Deser; Burcu Bayoglu; Kazım Besirli; Mujgan Cengiz; Berk Arapi; Yerik Junusbekov; Ahmet Dirican; Caner Arslan
Journal:  Heart Vessels       Date:  2015-10-05       Impact factor: 2.037

4.  An Orally Available NLRP3 Inflammasome Inhibitor Prevents Western Diet-Induced Cardiac Dysfunction in Mice.

Authors:  Salvatore Carbone; Adolfo G Mauro; Andrea Prestamburgo; Matthew S Halquist; Pratyush Narayan; Nicola Potere; Eleonora Mezzaroma; Benjamin W Van Tassell; Antonio Abbate; Stefano Toldo
Journal:  J Cardiovasc Pharmacol       Date:  2018-12       Impact factor: 3.105

Review 5.  The Importance of NLRP3 Inflammasome in Heart Failure.

Authors:  Brittany Butts; Rebecca A Gary; Sandra B Dunbar; Javed Butler
Journal:  J Card Fail       Date:  2015-05-14       Impact factor: 5.712

6.  Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse.

Authors:  Carlo Marchetti; Stefano Toldo; Jeremy Chojnacki; Eleonora Mezzaroma; Kai Liu; Fadi N Salloum; Andrea Nordio; Salvatore Carbone; Adolfo Gabriele Mauro; Anindita Das; Ankit A Zalavadia; Matthew S Halquist; Massimo Federici; Benjamin W Van Tassell; Shijun Zhang; Antonio Abbate
Journal:  J Cardiovasc Pharmacol       Date:  2015-07       Impact factor: 3.105

7.  Peripheral proinflammatory markers are upregulated in abstinent alcohol-dependent patients but are not affected by cognitive bias modification: Preliminary findings.

Authors:  Jeanelle Portelli; Corinde E Wiers; Xiaobai Li; Sara L Deschaine; Gray R McDiarmid; Felix Bermpohl; Lorenzo Leggio
Journal:  Drug Alcohol Depend       Date:  2019-09-11       Impact factor: 4.492

8.  Biomarkers of Endothelial, Renal, and Platelet Dysfunction in Stage 5 Chronic Kidney Disease Hemodialysis Patients With Heart Failure.

Authors:  Ryan McMillan; Leonidas Skiadopoulos; Debra Hoppensteadt; Nil Guler; Vinod Bansal; Ravipresenna Parasuraman; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2017-10-08       Impact factor: 2.389

Review 9.  Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury.

Authors:  Stefano Toldo; Adolfo G Mauro; Zachary Cutter; Antonio Abbate
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-31       Impact factor: 4.733

10.  Effects of exogenous ghrelin administration and ghrelin receptor blockade, in combination with alcohol, on peripheral inflammatory markers in heavy-drinking individuals: Results from two human laboratory studies.

Authors:  Mehdi Farokhnia; Jeanelle Portelli; Mary R Lee; Gray R McDiarmid; Vikas Munjal; Kelly M Abshire; Jillian T Battista; Brittney D Browning; Sara L Deschaine; Fatemeh Akhlaghi; Lorenzo Leggio
Journal:  Brain Res       Date:  2020-04-24       Impact factor: 3.252
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.